InflaRx N.V. ( IFRX ) NASDAQ Global Select

Cena: 0.78 ( -2.0% )

Aktualizacja 06-13 22:00
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 62
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 88%
Ilość akcji: 58 883 300
Debiut giełdowy: 2017-11-07
WWW: https://www.inflarx.de
CEO: Dr. Niels C. Riedemann M.D., Ph.D.
Adres: Winzerlaer Str. 2
Siedziba: 07745 Jena
ISIN: NL0012661870
Opis firmy:

Inflarx N.V., firma biofarmaceutyczna na etapie klinicznym, odkrywa i rozwija inhibitory za pomocą technologii C5A głównie w Niemczech i Stanach Zjednoczonych. C5A firmy jest zapalnym mediatorem, który bierze udział w postępie różnych chorób autoimmunologicznych i innych chorób zapalnych. Jego głównym kandydatem na produkt jest Vilobelimab, nowe dożylnie dostarczone pierwszorzędne przeciwciało anty-C5A, które zakończyło badanie kliniczne fazy III w leczeniu zapalenia hidradenicznego suppurativa, rzadkie i przewlekłe wyniszczające układowe choroby zapłonowe; W leczeniu przeciwciał przeciwneodrofilowych przeciwciała naczyniowych związanych z zapaleniem naczyń, rzadkiej i zagrażającej życiu choroby autoimmunologicznej, która jest w badaniu fazy II; w leczeniu pyodermy gangraenosum, przewlekłego zapalnego zaburzenia skóry, które jest w badaniu eksploracyjnym fazy IIA; oraz do leczenia inhibitora PD-1/PD-L1 odpornego na oporne/oporne na leczenie zaawansowane lokalnie lub przerzutowe rak skórny płaskonabłonkowy, który znajduje się w stadium rozwoju klinicznego fazy II. Firma opracowuje również Inf904, kandydata doustnego, małego cząsteczki do nieujawnionych przewlekłych chorób zapalnych i autoimmunologicznych; i IFX002, który jest w etapie rozwoju przedklinicznego w leczeniu przewlekłego stanu zapalnego i chorób autoimmunologicznych. Ma umowę o wspólnym rozwoju z Beijing Defengrei Biotechnology Co. Ltd.; oraz Umowa o współpracy i dostawach klinicznych z Merck & Co. Inc. Firma była wcześniej znana jako strażak B.V. i zmieniła nazwę na Inflarx N.V. w 2017 r. Inflarx N.V. został założony w 2007 r. I ma siedzibę w Jena w Niemczech.

Wskaźniki finansowe
Kapitalizacja (USD) 52 632 507
Aktywa: 79 687 764
Cena: 0.78
Wskaźnik Altman Z-Score: -1.0
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -0.9
Ilość akcji w obrocie: 88%
Średni wolumen: 478 968
Ilość akcji 67 133 300
Wskaźniki finansowe
Przychody TTM 168 652
Zobowiązania: 14 405 339
Przedział 52 tyg.: 0.711 - 2.815
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.8
P/E branży: 26.1
Beta: 1.576
Raport okresowy: 2025-08-06
WWW: https://www.inflarx.de
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Camilla Chong M.D. Chief Medical Officer 0 1966
Mr. Jan Medina CFA Head of Investor Relations & Vice President 0 0
Dr. Niels C. Riedemann M.D., Ph.D. Co-Founder, Chief Executive Officer & Executive Director 0 1973
Ms. Nicole Bertsch Senior Director & Head of Human Resources 0 0
Dr. Bruce P. Burnett Ph.D. Vice President & Head of Medical Affairs 0 0
Dr. Thomas Taapken Ph.D. Chief Financial Officer 0 1965
Prof. Renfeng Guo M.D. Co-Founder, Chief Scientific Officer & Executive Director 0 1970
Mr. Christian Schmid Vice President and Head of Legal Affairs & General Counsel 0 0
Dr. Maria Habel PH.D. Vice President, Head of Preclinical R&D and QC 0 1982
Ms. Derval O'Carroll Senior Vice President and Global Head of Regulatory Affairs & Compliance 0 1966
Wiadomości dla InflaRx N.V.
Tytuł Treść Źródło Aktualizacja Link
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update. globenewswire.com 2025-05-07 11:30:00 Czytaj oryginał (ang.)
InflaRx to Report First Quarter 2025 Results on May 7, 2025 JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. globenewswire.com 2025-04-30 11:30:00 Czytaj oryginał (ang.)
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com 2025-03-26 12:35:23 Czytaj oryginał (ang.)
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025. globenewswire.com 2025-03-20 09:30:00 Czytaj oryginał (ang.)
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses. globenewswire.com 2025-03-07 10:00:00 Czytaj oryginał (ang.)
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL. globenewswire.com 2025-02-28 11:00:00 Czytaj oryginał (ang.)
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. globenewswire.com 2025-02-25 09:30:00 Czytaj oryginał (ang.)
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. globenewswire.com 2025-02-18 18:01:00 Czytaj oryginał (ang.)
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. The purchase price of each pre-funded warrant is equal to the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which is the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are being sold by the Company. The offering is expected to close on February 18, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com 2025-02-13 23:45:00 Czytaj oryginał (ang.)
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are to be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. globenewswire.com 2025-02-13 18:01:00 Czytaj oryginał (ang.)
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY. globenewswire.com 2025-01-23 09:30:00 Czytaj oryginał (ang.)
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS. zacks.com 2025-01-16 13:50:20 Czytaj oryginał (ang.)
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only treatment approved in the European Union for the treatment of SARS-CoV-2-induced ARDS. globenewswire.com 2025-01-15 14:30:00 Czytaj oryginał (ang.)
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company's oral C5aR inhibitor, INF904. globenewswire.com 2024-12-20 09:30:00 Czytaj oryginał (ang.)
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygenation (ECMO)). The Company expects the European Commission to adopt the positive opinion and issue a marketing authorization within 67 days. globenewswire.com 2024-11-15 09:51:00 Czytaj oryginał (ang.)
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates InflaRx N.V. (IFRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. zacks.com 2024-11-08 11:40:14 Czytaj oryginał (ang.)
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update JENA, Germany, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced financial results for the three and nine months ended September 30, 2024, and provided an operating update. globenewswire.com 2024-11-08 09:30:00 Czytaj oryginał (ang.)
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024. globenewswire.com 2024-09-25 11:30:00 Czytaj oryginał (ang.)
3 Penny Stocks To Buy With Just $750 Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky. 247wallst.com 2024-09-24 14:36:54 Czytaj oryginał (ang.)
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company's novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. globenewswire.com 2024-09-03 11:30:00 Czytaj oryginał (ang.)
InflaRx Announces Participation in September Investor Events JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows: globenewswire.com 2024-08-27 11:30:00 Czytaj oryginał (ang.)
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates InflaRx N.V. (IFRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. zacks.com 2024-08-08 13:50:23 Czytaj oryginał (ang.)
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update JENA, Germany, Aug. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced financial results for the three and six months ended June 30, 2024, and provided an operating update. globenewswire.com 2024-08-08 11:30:00 Czytaj oryginał (ang.)
InflaRx to Report Second Quarter 2024 Results on August 8, 2024 JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned. globenewswire.com 2024-08-01 11:30:00 Czytaj oryginał (ang.)
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS). globenewswire.com 2024-06-24 12:02:00 Czytaj oryginał (ang.)
InflaRx Hosts R&D Event Highlighting the Promise of INF904 JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company's oral small molecule C5aR inhibitor, INF904. Speakers provided additional details on development rationales and plans for INF904, as well as additional insight into its potential role in CSU and HS and its broader therapeutic potential in the immuno-inflammation field. globenewswire.com 2024-06-05 16:00:00 Czytaj oryginał (ang.)
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego. globenewswire.com 2024-05-21 18:30:00 Czytaj oryginał (ang.)
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update JENA, Germany, May 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced financial results for the three months ended March 31, 2024, and provided an operating update. globenewswire.com 2024-05-08 11:30:00 Czytaj oryginał (ang.)
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City. globenewswire.com 2024-04-24 11:30:00 Czytaj oryginał (ang.)
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20. zacks.com 2024-03-21 11:46:05 Czytaj oryginał (ang.)
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans JENA, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial and operating results for the year ended December 31, 2023, and provided a comprehensive strategic update on its future development and operational plans. globenewswire.com 2024-03-21 09:00:00 Czytaj oryginał (ang.)
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company's anticipated development plans for INF904, InflaRx's orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call. globenewswire.com 2024-03-19 09:30:00 Czytaj oryginał (ang.)
InflaRx Appoints Jan Medina as Head of Investor Relations JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. globenewswire.com 2024-02-22 09:30:00 Czytaj oryginał (ang.)